Private Equity Driving Dynamic CRO Growth
Published: November 2015 by CenterWatch
Private equity (PE), which has been very active in the CRO space over the past five years, is reshaping the CRO landscape—giving the industry financial stability it might not otherwise have and providing the capital for CROs to expand, both organically and inorganically, to offer a broader range of services and greater efficiency to support R&D operations. The white paper delves into exactly how, and to what extent, PE is driving CRO growth.
- PE has changed the look of the industry over the past 10 years.
- It has added a level of credibility to the space by being willing to buy an asset like a CRO.
- PE gives the ability to develop long-term strategies that better integrate drug development services and improve R&D innovations.
Learn more »